Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility

被引：29
|
作者：
Van Baelen, Kurt [1 ]
Van Eygen, Veerle [1 ]
Rondelez, Evelien [1 ]
Stuyver, Lieven J. [1 ]
机构：
[1] Virco BVBA, B-2800 Mechelen, Belgium
来源：
AIDS | 2008年 / 22卷 / 14期
关键词：
D O I：
10.1097/QAD.0b013e32830f9703
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The contribution of clade-specific polymorphisms in the HIV-1 integrase gene towards integrase inhibitor phenotypic susceptibility was tested on 137 clinical isolates, of which 60 were non-clade B strains. Control Q148R mutant virus showed fold change values of 17.85 +/- 2.77 and 88.94 +/- 9.02 for raltegravir and elvitegravir, respectively, whereas the average fold change for the clinical samples was 0.91 +/- 0.40, and 0.84 +/- 0.37. Phenotypic testing proved that clade-specific integrase polymorphisms do not contribute to reduced susceptibility towards integrase inhibitors.
引用
收藏
页码：1877 / 1880
页数：4
相关论文
共 50 条
  • [21] Clade-Specific Alterations within the HIV-1 Capsid Protein with Implications for Nuclear Translocation
    Dick, Alexej
    Meuser, Megan E.
    Cocklin, Simon
    BIOMOLECULES, 2022, 12 (05)
  • [22] Elvitegravir: a once-daily inhibitor of HIV-1 integrase
    Wills, Todd
    Vega, Vivian
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (03) : 395 - 401
  • [23] HIV-1 Group O Integrase Displays Lower Enzymatic Efficiency and Higher Susceptibility to Raltegravir than HIV-1 Group M Subtype B Integrase
    Depatureaux, Agnes
    Quashie, Peter K.
    Mesplede, Thibault
    Han, Yingshan
    Koubi, Hannah
    Plantier, Jean-Christophe
    Oliveira, Maureen
    Moisi, Daniela
    Brenner, Bluma
    Wainberg, Mark A.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (12) : 7141 - 7150
  • [24] Relative fitness of raltegravir resistance mutants in HIV-1 integrase
    Hu, Z.
    Sun, W.
    Yu, T.
    Giguel, F.
    Kuritzkes, D. R.
    ANTIVIRAL THERAPY, 2008, 13 (04) : A84 - A84
  • [25] Reduced HIV-1 integrase flexibility as a mechanism for raltegravir resistance
    Kovari, L. C.
    Dewdney, T.
    Wang, Y.
    Kovari, I. A.
    ANTIVIRAL THERAPY, 2013, 18 : A116 - A116
  • [26] Humanized Mice to Assess the HIV-1 Clade-Specific Differences: Apropos of Viral Virulence and Neuropathology
    Gorantla, S.
    Makarov, E.
    Akther, S.
    Wood, C.
    Gendelman, H. E.
    Poluektova, L.
    JOURNAL OF NEUROIMMUNE PHARMACOLOGY, 2012, 7 : S67 - S68
  • [27] Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors (vol 6, pg 25, 2009)
    Serrao, Erik
    Odde, Srinivas
    Ramkumar, Kavya
    Neamati, Nouri
    RETROVIROLOGY, 2009, 6
  • [28] Examining structural analogs of elvitegravir as potential inhibitors of HIV-1 integrase
    Kavita Shah
    Saumya Gupta
    Hirdyesh Mishra
    Prashant K. Sharma
    Amit Jayaswal
    Archives of Virology, 2014, 159 : 2069 - 2080
  • [29] Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor
    Lampiris, Harry W.
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2012, 10 (01) : 13 - 20
  • [30] Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium
    Nguyen, Bach-Yen T.
    Isaacs, Robin D.
    Teppler, Hedy
    Leavitt, Randi Y.
    Sklar, Peter
    Iwamoto, Marian
    Wenning, Larissa A.
    Miller, Michael D.
    Chen, Joshua
    Kemp, Ramon
    Xu, Wei
    Fromtling, Robert A.
    Vacca, Joseph P.
    Young, Steven D.
    Rowley, Michael
    Lower, Michael W.
    Gottesdiener, Keith M.
    Hazuda, Daria J.
    PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: WINNERS AND FINALIST CANDIDATES OF THE PRIX GALIEN USA, INTERNATIONAL, AND PRO BONO HUMANITARIAN AWARDS 2010, 2011, 1222 : 83 - 89
12345